European Medical Solutions

ENXTBR:ALEMS 주식 보고서

시가총액: €28.3m

European Medical Solutions 과거 수익 실적

과거 기준 확인 0/6

European Medical Solutions has been growing earnings at an average annual rate of 52.3%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 51.4% per year.

주요 정보

52.3%

수익 성장률

84.4%

EPS 성장률

Biotechs 산업 성장-3.6%
매출 성장률51.4%
자기자본 수익률-10.6%
순이익-2.4%
최근 수익 업데이트30 Jun 2024

최근 과거 실적 업데이트

Recent updates

Would DMS Imaging (EBR:ALIMG) Be Better Off With Less Debt?

Jun 15
Would DMS Imaging (EBR:ALIMG) Be Better Off With Less Debt?

DMS Imaging SA (EBR:ALIMG) Soars 29% But It's A Story Of Risk Vs Reward

Dec 21
DMS Imaging SA (EBR:ALIMG) Soars 29% But It's A Story Of Risk Vs Reward

DMS Imaging SA's (EBR:DMSIM) Subdued P/S Might Signal An Opportunity

Jun 15
DMS Imaging SA's (EBR:DMSIM) Subdued P/S Might Signal An Opportunity

Here's Why DMS Imaging (EBR:DMSIM) Can Manage Its Debt Responsibly

Dec 29
Here's Why DMS Imaging (EBR:DMSIM) Can Manage Its Debt Responsibly

수익 및 비용 분석

European Medical Solutions 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.


수익 및 매출 내역

ENXTBR:ALEMS 수익, 비용 및 수입 (EUR Millions )
날짜수익수익G+A 비용R&D 비용
30 Jun 2444-1130
31 Mar 2443-1130
31 Dec 2343-1120
30 Sep 2341-1120
30 Jun 2340-1120
31 Mar 2338-3120
31 Dec 2237-6110
30 Sep 2266-7190
30 Jun 2257-4170
31 Mar 2248-2140
31 Dec 21380110
30 Sep 210210
30 Jun 210010
31 Mar 210-110
31 Dec 200-110
30 Sep 200-524
30 Jun 200-927
31 Mar 201-12310
31 Dec 191-16414
30 Sep 191-16313
30 Jun 191-17313
31 Mar 191-16312
31 Dec 181-14310
30 Sep 181-12310
30 Jun 181-1139
31 Mar 181-11210
31 Dec 171-12211
30 Sep 171-12211
30 Jun 172-12212
31 Mar 172-12212
31 Dec 162-12212
30 Sep 161-12211
30 Jun 160-12111
31 Mar 160-1019
31 Dec 150-817
31 Dec 140-413
31 Dec 130-212

양질의 수익: ALEMS is currently unprofitable.

이익 마진 증가: ALEMS is currently unprofitable.


잉여현금흐름 대 수익 분석


과거 수익 성장 분석

수익추이: ALEMS is unprofitable, but has reduced losses over the past 5 years at a rate of 52.3% per year.

성장 가속화: Unable to compare ALEMS's earnings growth over the past year to its 5-year average as it is currently unprofitable

수익 대 산업: ALEMS is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


자기자본 수익률

높은 ROE: ALEMS has a negative Return on Equity (-10.58%), as it is currently unprofitable.


자산 수익률


고용 자본 수익률


과거 성과가 우수한 기업 찾기